Covid-19 | China authorises CoronaVac for children above 3 years

Sinovac has finished the Phrase I and II clinical research stage, officials said.

June 06, 2021 05:53 pm | Updated 05:54 pm IST - Beijing

Employees pick up vials containing CoronaVac, Sinovac’s vaccine against the coronavirus disease (COVID-19), as they put them in trays before boxing.

Employees pick up vials containing CoronaVac, Sinovac’s vaccine against the coronavirus disease (COVID-19), as they put them in trays before boxing.

China has authorised the emergency use of CoronaVac, a COVID-19 vaccine manufactured by Chinese firm Sinovac, for children aged between 3 and 17 years, Sinovac Chairman Yin Weidong said.

"But when the vaccine will be put into (emergency) use, and starting from what age in the group has yet to be decided," he was quoted as saying by the state-run Global Times on Sunday.

Sinovac has finished the Phrase I and II clinical research stage, involving several hundred volunteers in this age group, which has proved that the vaccine is as safe and efficient as it is for adults, Yin told China Central Television in an interview on Friday.

The Wold Health Organisation (WHO) has granted approval on June 1 to China's second COVID-19 vaccine, Sinovac, which was expected to strengthen China’s vaccine diplomacy.

Earlier, WHO granted a similar approval to China’s Sinopharm. Besides administering the vaccines at home, China has been donating and exporting the vaccines to number of countries as part of its vaccine diplomacy.

China’s National Health Commission said on Sunday that over 763 million doses of COVID-19 vaccines had been administered across China so far.

For its part, China has approved about five of its vaccines for emergency use.

China has offered 10 million vaccine doses to COVAX facility which is WHO backed initiative to provide vaccines to developing countries.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.